Table 1.

Clinicopathologic characteristics for patients with IBC and non-IBC used for immunohistochemistry, RT-PCR, cDNA microarray, and NF-κB DNA-binding experiments

Immunohistochemistry (n = 90)
PCR (n = 37)
cDNA array (n = 34)
DNA-binding assays (n = 17)
Non-IBC (n = 46)IBC (n = 44)Non-IBC (n = 20)IBC (n = 17)Non-IBC (n = 18)IBC (n = 16)Non-IBC (n = 10)IBC (n = 7)
Age (y)
    Median (range)59 (33-81)59 (33-83)61 (42-78)56 (41-74)61 (42-78)56 (41-74)62 (33-78)56 (49-74)
Histologic type
    Ductal394118151614107
    Lobular73222200
Tumor emboli in dermal lymph vessels
    Present82821421334
    Absent381618316373
Grade*
    1110605030
    22520888733
    31024695944
T stadium
    1140605020
    2110403040
    3100707030
    4114431731617
N stadium
    0191807020
    1241611610571
    232711111116
ER status
    ER−1732111391275
    ER+2912949432
PR status§
    PR−2034111381272
    PR+26109410435
  • * According to the Elston-Ellis modification of the SBR grading system.

  • The N stadium for patients with IBC was determined clinically.

  • ER status was determined using the anti-ER antibody (clone 1D5) and a cutoff level of 10% to discriminate between the absence or presence of nuclear protein expression.

  • § PR status was determined using the anti-PR antibody (clone PgR636) and a cutoff level of 10% to discriminate between the absence or presence of nuclear protein expression.